default author photo

Andrea A. Berry

- Center for Vaccine Development and Global Health

SCHOLARLY PAPERS

2

DOWNLOADS

330

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Dose-Escalation, Double-Blind, Placebo-Controlled Evaluation of MAM01 Human Monoclonal Antibody for Protection Against Malaria: A First-in-Human, Phase 1 Adaptive Trial

Number of pages: 25 Posted: 23 Jun 2025
University of Maryland, Baltimore (UMB), - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB) - School of Medicine, affiliation not provided to SSRN, University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute and Gates Medical Research Institute
Downloads 200 (380,469)

Abstract:

Loading...

Malaria, Monoclonal antibody, Plasmodium falciparum, Circumsporozoite Protein, Repeat region, MAM01, Phase 1 trial, Subcutaneous, Intravenous

2.

Optimization of the CIS43LS Malarial Monoclonal Antibody and Protection Against Malaria

Number of pages: 26 Posted: 07 Oct 2022
University of Maryland, Baltimore (UMB), - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Government of the United States of America - Biostatistics Research Branch, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB), - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, Walter Reed Army Institute of Research, Walter Reed Army Institute of Research, Peking University, School of Public Health, Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, University of California, San Diego (UCSD), Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Peking University, School of Public Health, Vaccine Research Center, Government of the United States of America - Vaccine Research Center and Independent
Downloads 130 (558,171)

Abstract:

Loading...

Malaria, monoclonal antibody, Plasmodium falciparum, Circumsporozoite Protein, Subcutaneous, CIS43LS